7月30日，现货黄金刚刚突破3330.00美元/盎司关口，最新报3330.84美元/盎司，日内涨0.14%。 | | | 伦敦金现(SPTAUUSDOZ) 交易中 07-30 09:28:57 | | | 6 | | --- | --- | --- | --- | --- | --- | | 3330.84 = 0.00 | | | 昨结 3326.05 持仓 0 | | | | 4.79 | 0.14% | 量0 | | 昨收 3326.05 日增 0.00 | | | 分时 3333.455 | 五日 | 日K | 周Ｋ ■ 0.22% | | 月K 更多, 0 盘口 | | | | | | 卖1 3330.920 | | | | | | | | 买1 3330.840 | | | | | | | 09:28 3330.76 | | R.050 | | | 0.00% | | 09:28 3330.75 | | | | | | | 09:28 3330.766 0 | | | | | | | 09:28 3330.75 0 | | | | | | | 09:28 3330.598 0 | | 3318.6 ...

7月30日，隔夜美股三大指数集体收跌，截至收盘，道琼斯指数跌0.46%，报44,632.99点；标普500指数跌0.3%， 报6,370.86点；纳斯达克指数跌0.38%，报21,098.29点。科技股成为拖累大盘的主要力量，Meta跌超2%，英特尔、 苹果、特斯拉均跌超1%，AMD逆势上涨2%。传统行业方面，减肥药概念遭遇重挫，诺和诺德暴跌21%，礼来跌 超5%，联合包裹跌幅超过10%。 热门中概股全线承压，纳斯达克中国金龙指数当日收跌1.35%，成分股中76%的个股下跌。百度、京东等互联网巨 头表现疲软，百度跌2.9%至86.8美元，京东跌超3%至32.22美元，阿里巴巴跌2.28%，拼多多跌1.15%，哔哩哔哩 跌1.73%，网易跌0.27%，腾讯音乐涨0.69%，小马智行跌8.52%。 新能源汽车板块整体低迷，小鹏汽车跌近3%，蔚来汽车跌超2%，股价分别收于18.4美元和4.71美元。其中，理想 汽车（LI.US）盘前一度上涨6%，最终未能维持涨势。截至收盘，公司股价收盘大跌6.2%至27.38美元，成交额达 6.65亿美元。 理想汽车7月29日刚刚发布首款纯电SUV理想i8，尽管新车定价与增程版L8 ...

Market Overview - On July 30, A-shares opened lower with all three major indices declining: Shanghai Composite Index down 0.04%, Shenzhen Component Index down 0.23%, and ChiNext Index down 0.45% [1] Sector Performance - The coal and oil sectors, along with composite copper foil and rare earth permanent magnet concepts, showed notable gains [1] - Conversely, sectors such as weight loss drugs, CXO concepts, insurance, and pharmaceuticals experienced significant declines [1]

该公司表示，Wegovy在现金支付渠道的渗透率低于预期，主要受到仿制药持续冲击影响。此外，旗舰 糖尿病药物Ozempic（注：中文商品名为"诺和泰"，司美格鲁肽的糖尿病适应症制剂）也面临美国市场 竞争加剧的压力。 诺和诺德将于8月6日发布二季度财报，新华财经注意到此前已有市场机构表示对公司业绩担忧，此次提 前发布业绩预警确定了市场猜想。 诺和诺德29日同时宣布，任命Maziar Mike Doustdar 为新任总裁兼首席执行官，该任命将于8月7日生 效。 新华财经北京7月30日电（可达）截至29日美股收盘，减肥药概念板块大跌，美股丹麦药企诺和诺德股 价大跌超21%。 | 诺和诺德 NVO | | | | --- | --- | --- | | 54. 990 | -14.010 | -20.30% | | 盘前现价 | 53.970盘前涨幅 | -21.783% | | 盘前涨跌 | -15.030美东时间 | 10:29 | | 卖价 | | | 诺和诺德美股盘前发布业绩预警，大幅下调2025年全年销售和营业利润增长预期，主要原因是旗舰减肥 药物Wegovy（注：中文商品名为"诺和盈"，司美格鲁肽的减肥适 ...

当地时间周二，美股市场生出一丝"寒意"，三大指数集体收跌。截至收盘，道指跌0.46%，报44632.99点；纳指跌 0.38%，报21098.29点；标普500指数跌0.30%，报6370.86点。美联储即将结束为期2天的议息会议，据CME"美联储观 察"，美联储7月维持利率不变的概率为97.4%，降息25个基点的概率为2.6%。 个股方面，"网红"减重药司美格鲁肽制造商诺和诺德29日股价暴跌超21%。消息面上，由于减重"招牌"销售失速，且 在海外市场渗透率低于目标，公司将营业利润增长预期从之前的16%—24%下调至10%—16%。而这已经是诺和诺德今 年第二次下调业绩预期。 国际局势方面，据新华社消息，美国总统特朗普29日称，他把俄罗斯与乌克兰达成和平协议的最后期限设定为10天， 从当天开始计算。如果俄方没有就此取得进展，将面临美国新的制裁。 美股三大指数集体收跌 当地时间7月29日，美股三大指数集体收跌。截至收盘，道指跌204.57点，跌幅0.46%，报44632.99点；纳指跌80.29 点，跌幅0.38%，报21098.29点；标普500指数跌18.91点，跌幅0.30%，报6370.86点。 热门科 ...

Market Overview - The three major U.S. stock indices closed lower, with the Dow Jones down 0.46% at 44,632.99 points, the S&P 500 down 0.30% at 6,370.86 points, and the Nasdaq down 0.38% at 21,098.29 points [2][3] - Popular tech stocks led the decline, with the U.S. Tech Giants Index down 0.59%, Facebook down over 2%, and Tesla, Apple, and Intel down over 1% [3] Company Performance - Starbucks reported Q3 net revenue of $9.5 billion, up from $9.11 billion year-over-year, exceeding analyst expectations of $9.29 billion. Adjusted EPS was $0.50, below the expected $0.65. Same-store sales in China grew by 2%, surpassing the expected 1.44% [8] - Visa's Q3 net revenue reached $10.2 billion, up from $8.9 billion year-over-year, beating analyst expectations of $9.83 billion. Adjusted EPS was $2.98, above the forecast of $2.85 [10] Sector Movements - The weight loss sector saw significant declines, with Novo Nordisk dropping over 21%. United Parcel Service fell over 10% due to Q2 earnings impact, while Eli Lilly and FedEx dropped 5.59% and over 3%, respectively [4] - The oil and gas sector showed strength, with ExxonMobil, Shell, and Imperial Oil rising over 1% [6] Chinese Stocks - The Nasdaq Golden Dragon China Index fell 1.35%, with major Chinese stocks mostly declining. Li Auto dropped over 6%, JD.com fell over 3%, and Baidu declined nearly 3% [5] Federal Reserve Focus - The market is awaiting the Federal Reserve's monetary policy meeting, with a 97.9% probability that interest rates will remain unchanged. The probability of a 25 basis point cut in September is 63.2% [11][14]

Market Overview - The US stock market experienced a collective decline, with major indices such as the Dow Jones, S&P 500, and Nasdaq all closing lower. Notably, the Dow fell by 0.46% to 44,632.99 points, the S&P 500 dropped by 0.30% to 6,370.86 points, and the Nasdaq decreased by 0.38% to 21,098.29 points [5][6][4]. Company Performance - Notable declines were observed in popular tech stocks, with the "Big Seven" tech index down by 0.59%. Facebook saw a drop of over 2%, while Tesla, Apple, and Intel each fell by more than 1%. Conversely, Google experienced a rise of 1.56% [7][8]. - Novo Nordisk, a leader in the weight loss drug sector, plummeted by over 21%. Other companies in the logistics sector, such as United Parcel Service, fell by over 10%, while Eli Lilly and FedEx dropped by 5.59% and over 3%, respectively [9][11]. Key Earnings Reports - Starbucks reported a third-quarter net revenue of $9.5 billion, up from $9.11 billion year-over-year, surpassing analyst expectations of $9.29 billion. However, adjusted earnings per share were $0.50, below the forecast of $0.65. Same-store sales in China grew by 2%, exceeding the expected growth of 1.44% [15][16]. - Visa's third-quarter net revenue reached $10.2 billion, compared to $8.9 billion in the same period last year, also beating analyst expectations of $9.83 billion. Adjusted earnings per share were $2.98, slightly above the forecast of $2.85. However, Visa's stock fell by 2.52% in after-hours trading [17]. Commodity Market - The commodity market saw an uptick, with COMEX gold futures rising by 0.48% to $3,383 per ounce, and silver futures increasing by 0.43% to $38.385 per ounce. International oil prices also climbed, with Brent crude surpassing $72 per barrel, marking a daily increase of 3.88% [13].

减肥药概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002317 | 众生药 业 | 9.98 | 15.34 | 30259.16 | 13.39 | | 300122 | 智飞生 物 | 6.50 | 9.19 | 25584.13 | 8.11 | | 300765 | 新诺威 | 7.10 | 1.03 | 9329.48 | 13.00 | | 002294 | 信立泰 | 3.68 | 1.39 | 9194.53 | 11.73 | | 002038 | 双鹭药 业 | 7.09 | 9.67 | 7891.35 | 11.45 | | 002821 | 凯莱英 | 4.13 | 4.86 | 7719.47 | 4.12 | | 300199 | 翰宇药 业 | 4.97 | 21.02 | 7338.57 | 2.48 | | 000513 | 丽珠集 | 0.07 | 3.00 | ...

Core Viewpoint - The article discusses the recent administrative penalty imposed on Nuotai Bio (688076.SH) by the China Securities Regulatory Commission (CSRC) for financial misconduct, specifically for inflating its performance figures in its first year post-IPO. Group 1: Company Misconduct - Nuotai Bio was found to have engaged in performance fraud shortly after its IPO in May 2021, with the CSRC's investigation revealing that the company inflated its revenue by 30 million yuan and its total profit by 25.95 million yuan, which accounted for 20.64% of the reported profit for that year [2][3][10] - The fraudulent activity involved a technical transfer to Zhejiang Huabei Pharmaceutical Co., which lacked the financial capability to pay for the technology and did not have the means to utilize it effectively [3][4] - The actual controller of Nuotai Bio, Zhao Dezhong, was implicated in orchestrating the fraudulent activities, including arranging financing for the payment of the technical transfer [4][5] Group 2: Financial Impact - Despite the inflated figures, Nuotai Bio's actual performance in 2021 showed a revenue of 644 million yuan, a year-on-year increase of 13.58%, while the net profit decreased by 6.52% to 115 million yuan [10] - The company planned to issue convertible bonds in November 2022, which were approved in November 2023, raising 434 million yuan [6][8][9] - Following the CSRC's penalties, which totaled 47.4 million yuan for the company and 18 million yuan for Zhao Dezhong, the company's stock was placed under risk warning and subsequently suspended [11][12][14] Group 3: Market Reaction - The stock price of Nuotai Bio surged over 70% in the first half of 2024 due to the popularity of GLP-1 peptide drugs, but fell nearly 30% in October 2024 after the CSRC's investigation was made public [14] - Investors affected by the company's illegal activities may seek to recover losses through legal means [15]

Group 1 - The weight loss drug concept sector experienced a decline of 1.10%, ranking among the top declines in concept sectors, with notable declines from companies like Kexing Pharmaceutical, Yipinhong, and Ganli Pharmaceutical [1][2] - Among the 17 stocks that rose, Tainkang, *ST Sansheng, and Lanxiao Technology led with increases of 4.12%, 3.21%, and 2.31% respectively [1][2] - The weight loss drug sector saw a net outflow of 683 million yuan from main funds, with 33 stocks experiencing outflows, and 8 stocks seeing outflows exceeding 30 million yuan [2][4] Group 2 - Kexing Pharmaceutical had the highest net outflow of main funds at 116 million yuan, followed by Hanyu Pharmaceutical and Ganli Pharmaceutical with outflows of 112 million yuan and 109 million yuan respectively [2][4] - The stocks with the highest net inflow of main funds included Tainkang, Zhongsheng Pharmaceutical, and Changshan Pharmaceutical, with inflows of 34.43 million yuan, 23.74 million yuan, and 20.84 million yuan respectively [2][4] - The trading volume for Kexing Pharmaceutical was 7.99%, with a price drop of 14.19%, indicating significant trading activity despite the decline [3][4]